There is not enough irrefutable evidence that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists have positive effects on cognition in patients with type 2 diabetes mellitus (T2DM), according to a study.
A comprehensive toolkit tailored to arming primary care physicians (PCPs) with practical resources to help them identify, assess, and manage those at risk of fractures has recently been launched by the Asia Pacific Fragility Fracture Alliance (APFFA).
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Several weight-loss diets can simultaneously reduce serum urate concentrations and cardiovascular risk factors, effects that are mediated by excess pounds shed and improved insulin levels, as shown in a study.
A family history of diabetes appears to be unrelated to the risk of incident cardiovascular disease (CVD), reports a recent study. Parental myocardial infarction (MI) or stroke, however, may be linked to CVD onset.
Eating higher amounts of white rice raises the risk of diabetes, and this association is especially pronounced in South Asia, a study has found. Meanwhile, in other regions of the world, the risk is modest or inconsequential.
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.